View Report
September 13, 2024
Measured Result
9.68 mg
96.80% of label claim
Stealth Labs
Stealth Labs
Latest Laboratory Result 9.68 mg September 13, 2024 · 96.80% of label claim View
Survodutide 10 mg
Product Information Compound Details
Active Substance Survodutide Dual GLP-1/Glucagon receptor agonist
10 mg/vialStrength 10 mg/vial
Package 1 Vial
Form Lyophilized Powder
Vial Size 2 mL Vial
Drug Class Research Peptide
Manufacturer Stealth Labs
Packaging Notice Shipped Without Product Label This Stealth Labs product is supplied in an unlabeled vial.
Shipping :
International
U.S. Domestic
Out of stock
Product Overview
Survodutide 10 mg by Stealth Labs
Survodutide 10 mg is a lyophilized research peptide manufactured by Stealth Labs, supplied as 10 mg/vial of survodutide in a 2 mL vial.
Survodutide Lyophilized Powder
Survodutide 10 mg is a long-acting synthetic peptide that functions as a dual glucagon-like peptide-1 (GLP-1) and glucagon receptor agonist. It is under clinical investigation for metabolic dysfunction-associated steatohepatitis (MASH) and obesity. Survodutide is not FDA-approved for any indication and is available only within clinical trial settings.
Survodutide is designed to leverage the complementary mechanisms of GLP-1 and glucagon receptor agonism. GLP-1 activity enhances glucose-dependent insulin secretion, suppresses glucagon release, slows gastric emptying, and reduces appetite. The addition of glucagon receptor agonism is intended to increase energy expenditure and promote hepatic lipid metabolism, which may provide additional benefits for liver health and body composition beyond GLP-1 agonism alone.
Clinical trials have demonstrated dose-dependent reductions in body weight and improvements in liver enzymes. Common adverse events are predominantly gastrointestinal, including nausea, vomiting, and diarrhea. As a research chemical sold outside the pharmaceutical supply chain, this product has not undergone FDA review for safety, efficacy, or manufacturing quality.
Key Benefits of Survodutide 10 mg
- Dual GLP-1 and glucagon receptor agonist mechanism
- Lyophilized powder format for research applications
- 10 mg/vial concentration in a 2 mL vial
- Manufactured by Stealth Labs with published laboratory verification
- Research chemical — not for human use
Formulation
Lyophilized Powder
Survodutide 10 mg is supplied as a lyophilized (freeze-dried) powder in a 2 mL glass vial. Reconstitution with an appropriate solvent is required before use in research applications.
Product Profile
Survodutide Profile
Survodutide is a dual GLP-1/glucagon receptor agonist peptide under clinical investigation for metabolic liver disease and obesity.
Dual GLP-1/Glucagon Receptor Agonist
Survodutide is a synthetic peptide that activates both the GLP-1 receptor and the glucagon receptor. GLP-1 receptor agonism enhances glucose-dependent insulin secretion, suppresses glucagon release from pancreatic islet cells, slows gastric emptying, and reduces appetite through hypothalamic signaling. Glucagon receptor agonism is intended to increase energy expenditure and promote hepatic fatty acid oxidation.
This dual mechanism is being investigated for potential additive or synergistic effects on body weight and liver fat content. The glucagon component is thought to contribute to increased satiety and energy expenditure, while the GLP-1 component provides established metabolic benefits and mitigates glucagon's potential to raise blood glucose.
Survodutide is one of several multi-hormone receptor modulator (MHRM) peptides in clinical development, alongside other dual and triple agonists targeting GLP-1, GIP, and glucagon receptors. It remains investigational and is not FDA-approved for any indication.
Research Status
Investigational Only
Survodutide is currently in Phase 3 clinical trials for metabolic dysfunction-associated steatohepatitis (MASH) and obesity. It is not FDA-approved for any indication and is not available through licensed pharmacies or by standard prescription. Products sold under the name survodutide in the United States are research compounds not regulated by the FDA.
Survodutide 10 mg vs Other Stealth Labs Peptides
Stealth Labs offers Mazdutide and Cagrilintide as other research peptides commonly referenced in metabolic research contexts. Mazdutide is also a dual GLP-1/glucagon receptor agonist, while cagrilintide is an amylin analogue targeting amylin and calcitonin receptors.
Compared to TB 500, which is a thymosin beta-4 fragment studied for tissue healing, survodutide is a metabolic peptide with a distinct mechanism of action targeting appetite regulation and energy homeostasis. All are lyophilized powders requiring reconstitution, and none are FDA-approved for human use.
Laboratory Testing
Survodutide 10 mg Lab Reports
Published laboratory reports for Survodutide 10 mg are shown below with the test date, measured concentration and percentage of the product's 10 mg/vial label claim.
View Report
Laboratory results apply to the specific tested sample represented in each published report and should not be interpreted as a measurement of every vial or production batch.
Dosage & Usage
Survodutide 10 mg Dosage & Usage
The information below is provided for educational reference only. Survodutide is not FDA-approved for any indication. No human dosing information is established for non-clinical settings, and non-medical use falls outside any approved indication.
Clinical Trial Reference Ranges
Common reference ranges for survodutide in non-medical contexts are not well characterized in publicly available bodybuilding resources, and no FDA-approved dosing information exists. In clinical trials, survodutide has been administered as a once-weekly subcutaneous injection, with doses escalating over time. Clinical trial doses have ranged from approximately 0.3 mg to 6 mg per week in studies for MASH and obesity.
| Use Case | Clinical Trial Reference Range | Frequency |
|---|---|---|
| Phase 2 (MASH, investigational) | Dose escalation to 6 mg per week | Once weekly |
| Phase 3 (obesity, investigational) | Under investigation | Once weekly |
| Non-medical research | Not established | Not applicable |
Reconstitution & Handling
Survodutide is supplied as a lyophilized powder requiring reconstitution with an appropriate solvent such as bacteriostatic water or sterile saline. Once reconstituted, peptide solutions are more susceptible to degradation and should be stored refrigerated at 2–8°C. Avoid repeated freeze-thaw cycles, which can degrade the peptide and potentially increase immunogenicity risk.
Reconstitution should be performed gently by swirling rather than shaking to prevent denaturation or aggregation. A cloudy solution or visible particles may indicate incomplete dissolution, aggregation, or contamination and should not be used.
Managing Research Risks
In clinical trials, gastrointestinal adverse events have been the most commonly reported, including nausea, vomiting, diarrhea, and constipation. These are consistent with the GLP-1 receptor agonist class and are typically most pronounced during dose escalation. Because survodutide is investigational, no long-term safety data exist outside clinical trial settings.
GLP-1 receptor agonists carry class warnings for pancreatitis, gallbladder disease, and thyroid C-cell tumors based on rodent studies. As a research chemical product, this formulation has not undergone FDA review for purity, sterility, or actual content beyond the single laboratory report shown.
Post-Cycle Considerations
Survodutide is a peptide and does not suppress endogenous testosterone production. No post-cycle therapy is applicable or necessary for survodutide alone. If survodutide is referenced alongside anabolic compounds in non-medical contexts, any PCT protocol would be determined by the other compounds, not by survodutide.
Important
Individual Response Varies
No human clinical data exists to support any specific dosing strategy for survodutide in non-clinical settings. The information above is for educational reference only and does not constitute medical advice. Survodutide is not FDA-approved for any indication.
Safety & Information
Survodutide Safety Information
Survodutide is not FDA-approved for any indication. Its safety profile outside clinical trial settings is not characterized.
Important Safety Information
Survodutide is an investigational compound currently in Phase 3 clinical trials. It is not FDA-approved for any indication and is not available through licensed pharmacies or by standard prescription. Products sold in the United States under the name survodutide are research compounds not regulated by the FDA, with no verified manufacturing standards or safety oversight.
As a dual GLP-1/glucagon receptor agonist, survodutide may share class-related risks with other GLP-1 receptor agonists, including gastrointestinal adverse effects, pancreatitis, gallbladder disease, and potential thyroid C-cell tumor risk based on rodent studies.
Important
Not FDA-Approved
Survodutide is investigational and not approved for human use. Products sold online under the name survodutide through research compound vendors are not FDA-regulated, have no verified manufacturing standards, and carry unknown contamination, dosing, and safety risks.
Potential Adverse Effects
In clinical trials, gastrointestinal adverse events have been the most commonly reported with survodutide, including nausea, vomiting, diarrhea, and constipation. These are consistent with the GLP-1 receptor agonist class and are typically most pronounced during dose escalation.
GLP-1 receptor agonists as a class carry warnings for acute pancreatitis, acute gallbladder disease, hypoglycemia when used with insulin or secretagogues, acute kidney injury due to volume depletion, severe gastrointestinal reactions, and hypersensitivity reactions. Diabetic retinopathy complications and heart rate increases have also been reported with semaglutide, another GLP-1 receptor agonist.
Because survodutide remains investigational, no long-term safety data exist outside clinical trial settings, and cardiovascular outcomes data are not yet available.
Conditions Requiring Medical Evaluation
As survodutide is not approved for any indication, there are no established contraindications in non-clinical settings. In clinical trials, exclusion criteria have included type 1 diabetes, pregnancy or breastfeeding, and recent use of other GLP-1 receptor agonist medications. Individuals with a history of pancreatitis, severe gastrointestinal disease, or diabetic retinopathy should consult a qualified healthcare professional.
Monitoring During Research Use
No monitoring parameters have been established for survodutide outside clinical trial settings. Laboratory testing of the product itself, such as the published potency report shown in the Lab Reports tab, is separate from any clinical monitoring. Product testing does not assess individual health status or suitability for use.
Product Care
Storage & Handling
Lyophilized survodutide should be stored at -20°C or below for maximal stability, protected from moisture and light. Allow the vial to warm to room temperature before opening to prevent condensation.
Reconstituted survodutide should be stored refrigerated at 2–8°C and used within a reasonable timeframe. Avoid repeated freeze-thaw cycles, which can degrade the peptide. Keep all research peptides out of the reach of children.
Further Safety Information
Shipping & Authenticity
Shipping & Product Authenticity
Survodutide 10 mg is supplied through the official Stealth Labs distribution chain and shipped in original manufacturer packaging with discreet, privacy-focused handling.
USA Domestic
3–5 business days
International
10–15 business days
Order Processing
24–48 business hours
Tracking
Provided after dispatch
Direct Supply
Discreet Delivery & Original Packaging
The outer shipping package remains discreet, with privacy-focused handling and no unnecessary external product details. Products are supplied through the official Stealth Labs distribution chain.
What to Expect
- Orders are processed after payment confirmation
- USA Domestic shipping is typically faster when local stock is selected
- International orders include tracking, though update frequency may vary by destination
- Multiple warehouses may result in separate shipments when applicable
Authenticity Verification
To verify your Survodutide 10 mg product, use the security code on the vial label and cross-check it on the Stealth Labs official site. Official Stealth Labs presentation, batch-linked lab proof, and original packaging help reinforce product legitimacy and buyer confidence.
For complete delivery details, tracking policy, and reshipment terms, please see our Shipping Info page.
Storage
Survodutide 10 mg Storage
Proper storage conditions help preserve peptide stability and overall product integrity throughout shelf life.
Recommended Conditions
Lyophilized survodutide should be stored at -20°C or below for maximal stability, protected from moisture and light. Short-term storage at room temperature is relatively stable for weeks, but long-term storage requires freezing. Allow the vial to warm to room temperature before opening to prevent condensation.
Reconstituted survodutide should be stored refrigerated at 2–8°C and used within a reasonable timeframe. Avoid repeated freeze-thaw cycles, which can degrade the peptide. Inspect the solution before use and do not use if it appears cloudy, discolored, or contains particulate matter.
Quick Reference
Do & Don't
- Do store lyophilized powder at -20°C or below
- Do refrigerate reconstituted solution at 2–8°C
- Do allow vial to warm before opening
- Don't freeze reconstituted solution repeatedly
- Don't expose to excessive heat, light, or moisture
- Don't use if solution looks cloudy or contains particles
Frequently Asked Questions
Survodutide 10 mg FAQ
Answers to common questions about Survodutide 10 mg, its research status, clinical data, and laboratory testing.
What is Survodutide 10 mg used for?
Survodutide 10 mg is a lyophilized research peptide sold for laboratory use only. In clinical trials, survodutide has been investigated for metabolic dysfunction-associated steatohepatitis (MASH) and obesity. It is not FDA-approved for any indication and is available only within clinical trial settings.
How often should Survodutide 10 mg be used?
In clinical trials, survodutide is administered as a once-weekly subcutaneous injection with dose escalation over time. Clinical trial doses have ranged from approximately 0.3 mg to 6 mg per week. No dosing recommendation can be made for non-clinical settings, as survodutide is not FDA-approved.
Does Survodutide 10 mg require PCT?
Survodutide is a peptide, not a hormone, and does not suppress endogenous testosterone production. No post-cycle therapy is applicable or necessary for survodutide alone. If survodutide is referenced alongside anabolic compounds in non-medical contexts, any PCT protocol would be determined by the other compounds, not by survodutide.
What does survodutide do?
Survodutide is a dual GLP-1 and glucagon receptor agonist. GLP-1 receptor agonism enhances glucose-dependent insulin secretion, suppresses glucagon release, slows gastric emptying, and reduces appetite. Glucagon receptor agonism is intended to increase energy expenditure and promote hepatic fatty acid oxidation. This dual mechanism is being investigated for effects on body weight and liver fat content.
How long does survodutide take to work?
Clinical trial data for survodutide are still emerging, and the time to onset of effects has not been fully characterized. In trials of other GLP-1-based therapies, appetite suppression is typically noticed within weeks, with body weight and liver-related changes accumulating over months. The time required to notice effects depends on the individual and the specific outcome being evaluated.
Is survodutide the best weight management peptide?
There is no single agent that is universally best. Survodutide is investigational, and its efficacy and safety profile relative to FDA-approved options like semaglutide or tirzepatide has not been fully established. Non-medical use falls outside approved indications, and the compound is not FDA-approved.
What is the difference between survodutide and semaglutide?
Survodutide is a dual GLP-1 and glucagon receptor agonist, while semaglutide is a GLP-1 receptor agonist only. The addition of glucagon activity in survodutide is intended to provide additional metabolic benefits. Semaglutide is FDA-approved; survodutide is investigational.
What is the difference between survodutide and Mazdutide?
Both survodutide and Mazdutide are dual GLP-1/glucagon receptor agonists. Mazdutide is approved in China for weight management and type 2 diabetes but is not FDA-approved. Survodutide remains investigational in the United States. Both are sold as research peptides and require reconstitution.
Is 10 mg of Survodutide a lot?
A milligram amount cannot be classified as appropriate or excessive because survodutide is not FDA-approved and no non-clinical dosing information exists. It is also important to distinguish a total vial content from a dose. Survodutide 10 mg indicates the total peptide content per vial; that quantity does not by itself specify how much should be used in any research application.
What strength is Survodutide 10 mg?
Survodutide 10 mg is labeled at 10 mg of survodutide per vial. It is supplied as a lyophilized powder in a 2 mL vial.
Is Survodutide 10 mg lab tested?
Yes. A published laboratory report dated September 13, 2024 measured Survodutide 10 mg at 9.68 mg, equivalent to 96.80% of its 10 mg/vial label claim. The complete report can be viewed in the Lab Reports tab. Laboratory results apply to the tested sample represented by the individual report.
Can Survodutide 10 mg be stacked with other compounds?
Survodutide is not FDA-approved, and no clinical data exists to support any combination with other compounds outside of clinical trials. In clinical trials, survodutide has been studied as monotherapy. Stealth Labs offers Mazdutide and Cagrilintide as other research peptides, but combinations with survodutide lack clinical validation.
Related Offers
Lab Tested
Shipped USA Domestic
-40% OFF
Dragon Pharma, Europe
Product Information Compound Details
Active Substance Survodutide Dual GLP-1 / Glucagon Receptor Agonist
10 mg/vialStrength 10 mg/vial
Package 1 × 2 mL Vial
Form Lyophilized Powder
Drug Class Dual Receptor Agonist
Receptor Targets GLP-1 / Glucagon
Manufacturer Dragon Pharma
$102.00
$170.00
Shipped International
Bharat Serums And Vaccines Ltd, India
Drug Class: Natural Hormone
Active Substance: Pre-mixed Human Chorionic Gonadotropin 10000IU
Active Life: -
Average Dose: -
Liver Toxicity: No
Aromatization Rate: No
Anabolic Rate: Not a steroid
Androgenic Rate: Not a steroid
This Price Is Per amp (1 mL Each)
$90.00
Shipped International
Sun Pharma, India
Drug Class: Natural Hormone
Active Substance: Human Chorionic Gonadotropin 5000IU
Active Life: -
Average Dose: -
Liver Toxicity: No
Aromatization Rate: No
Anabolic Rate: Not a steroid
Androgenic Rate: Not a steroid
This Price Is Per amp (1 mL Each)
$70.00
Shipped International
Bharat Serums And Vaccines Ltd, India
Drug Class: Natural Hormone
Active Substance: Pre-mixed Human Chorionic Gonadotropin 5000IU
Active Life: -
Average Dose: -
Liver Toxicity: No
Aromatization Rate: No
Anabolic Rate: Not a steroid
Androgenic Rate: Not a steroid
This Price Is Per amp (1 mL Each)
$70.00
Lab Tested
Domestic & International
Dragon Pharma, Europe
Product Information Compound Details
Active Substance Human Chorionic Gonadotropin (HCG) Chorionic Gonadotropin for Injection
2,500 or 5,000 IU/vialVial Strength 2,500 IU or 5,000 IU
Package 1 × 2 mL Vial
Form Lyophilized Powder
Drug Class Gonadotropin
Hormone Type Glycoprotein Hormone
Manufacturer Dragon Pharma
$75.00